wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35752978-20D6A051-851F-4E32-8C3D-C456875270B2
Q35752978-20D6A051-851F-4E32-8C3D-C456875270B2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35752978-20D6A051-851F-4E32-8C3D-C456875270B2
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
P2860
Q35752978-20D6A051-851F-4E32-8C3D-C456875270B2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35752978-20D6A051-851F-4E32-8C3D-C456875270B2
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4210e1ffd356b92a101cbbf59e17d419545ac241
P2860
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.